<\/p>\n
Solu-Medrol<\/strong> is a sterile powder for reconstitution from Pfizer containing methylprednisolone sodium succinate 125 mg \/ 2 mL Act-O-Vial<\/strong> \u2014 en highly water-soluble pro-drug ester<\/strong> of methylprednisolone designed for rapid intravenous (IV) bolus or infusion<\/strong> when an immediate, large dose of glucocorticoid is needed. Onset of action is within minutes to 1 hour<\/strong>. Anv\u00e4nds f\u00f6r high-dose pulse therapy<\/strong> in MS relapse (1 g IV daily for 3–5 days), severe acute asthma, anaphylaxis after epinephrine, severe lupus or vasculitis flare, transplant rejection (induction and rescue), sight-threatening optic neuritis, and severe inflammatory ophthalmic disease. Lower doses (40–125 mg IV) are used as second-line in anaphylaxis, severe allergic reactions, and acute spinal cord injury (controversial). Pulse therapy carries a real risk of severe arrhythmia and sudden cardiac death<\/strong> — cardiac monitoring is standard during gram-doses. Other acute risks include severe psychiatric reaction, hyperglycaemia (especially in diabetes), and anaphylaxis to the drug itself. This is a hospital and supervised-clinic medication, not for patient self-administration.<\/strong><\/p>\n<\/div>\n <\/p>\n \ud83d\udce6 Varje best\u00e4llning omfattas av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 om din f\u00f6rs\u00e4ndelse inte anl\u00e4nder inom 20 arbetsdagar, skickar vi om den.<\/p>\n V\u00e5ra generiska l\u00e4kemedel kommer fr\u00e5n WHO-GMP-certifierade tillverkare och skickas v\u00e4rldsvidt i diskreta, enkla f\u00f6rpackningar \u2014 inget l\u00e4kemedelsnamn p\u00e5 f\u00f6rs\u00e4ndelsens utsida. Kortbetalningar hanteras via en reglerad betalningsprocessor (kontoutdrag visar en reglerad kortbetalningsprocessor \u2014 aldrig \u201cMedsBase\u201d eller n\u00e5got l\u00e4kemedelsnamn). Krypto och SEPA-bank\u00f6verf\u00f6ring accepteras ocks\u00e5. Varje best\u00e4llning backas upp av v\u00e5r Reshipment Assurance Policy.<\/p>\n Solu-Medrol is a sterile powder for reconstitution and intravenous bolus or infusion manufactured by Pfizer containing methylprednisolone sodium succinate<\/strong> — a synthetic corticosteroid in the glucocorticoid class. Glucocorticoids are the most powerful broad-spectrum anti-inflammatory and immunosuppressive drugs available, with effects across almost every tissue and organ system.<\/p>\n Solu-Medrol is Pfizer's original methylprednisolone sodium succinate — the standard hospital\/emergency-room IV steroid. The 125 mg \/ 2 mL Act-O-Vial is the most-stocked strength worldwide and is used for severe acute asthma, anaphylaxis (after epinephrine), severe COPD exacerbation, MS relapse (in combination with additional vials for gram-doses), transplant rejection and severe autoimmune flares. Designed for in-hospital or supervised-clinic use, not patient self-administration.<\/p>\n Methylprednisolone 4 mg is approximately equivalent to prednisolone 5 mg (potency ratio ~5). The physiological daily cortisol output of a healthy adult is approximately 5–7.5 mg of prednisolone-equivalent — any dose above that is “supraphysiological” and begins to suppress the hypothalamic-pituitary-adrenal (HPA) axis.<\/p>\n Why methylprednisolone sodium succinate IV?<\/strong> Methylprednisolone itself is poorly water-soluble — impossible to inject IV at the gram-doses needed for pulse therapy. The sodium succinate ester is highly water-soluble, dissolves rapidly in the supplied diluent, and is hydrolysed in the blood to active methylprednisolone within minutes. The Act-O-Vial dual-chamber design keeps powder and diluent separate until reconstitution, extending shelf life and reducing pharmacist preparation time in the emergency setting where every minute counts.<\/p>\n Methylprednisolone enters cells, binds the intracellular glucocorticoid receptor<\/strong>, and the receptor-drug complex translocates to the nucleus where it alters transcription of hundreds of genes. The end result is a broad dampening of the inflammatory cascade:<\/p>\n Clinical onset (IV): genomic anti-inflammatory effects within 1–4 hours<\/strong>. At gram-doses, additional rapid non-genomic membrane-stabilising effects<\/strong> appear within minutes, contributing to the immediate symptomatic benefit seen in MS relapse, severe asthma and acute spinal cord injury.<\/p>\n Solu-Medrol is used wherever an immediate, very large dose of glucocorticoid is needed and the patient cannot wait for oral absorption.<\/p>\n Solu-Medrol is inte<\/strong> appropriate for: maintenance therapy (switch to oral as soon as the patient can swallow), undiagnosed shock or sepsis without specialist review, or routine outpatient use.<\/p>\n Solu-Medrol is supplied as 125 mg \/ 2 mL Act-O-Vial<\/strong>. The Act-O-Vial dual-chamber system contains the lyophilised methylprednisolone sodium succinate powder in the upper chamber and the bacteriostatic water diluent in the lower chamber, separated by a stopper. Activate by pressing down on the plastic plunger to depress the stopper and release the diluent into the powder.<\/p>\nVarf\u00f6r best\u00e4lla fr\u00e5n MedsBase<\/h3>\n
What Is Solu-Medrol?<\/h2>\n
How Does Solu-Medrol Work?<\/h2>\n
\n
Anv\u00e4ndningsomr\u00e5den och indikationer<\/h2>\n
High-dose pulse therapy (gram-doses)<\/h3>\n
\n
Lower-dose IV (40–500 mg)<\/h3>\n
\n
Solu-Medrol Dosage and How to Use<\/h2>\n
Typical adult IV doses<\/h3>\n